Addmedica SAS

SEATTLE, July 16, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the North America sickle cell disease market is estimated to be valued at US$ 770.5 Million in 2021 and is expected to exhibit a CAGR of 16.2% over the forecast period (2021-2028). Key Trends and Analysis of the North America Sickle Cell Disease Market: Major players in the market are focused on grant programs (fund supports) for creating awareness and supporting the treatment of patients suffering from sickle cell disease in the U.S. For instance, in March 2021, Global Blood Therapeutics, Inc. (GBT), a pharmaceutical company, announced the launch of Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program in the U.S., which provides funding to accelerate the treatment development and sustainable access-to-care programs for people living with sickle cell disease (SCD). Furthermore, the companies are focusing on adoption of strategies such as acquisitions and collaborations in order to expand their product portfolio and strengthen their presence in the market. For instance, in December 2019, Global Blood Therapeutics, Inc. and Syros Pharmaceuticals, Inc. announced the collaboration to discover, develop, and commercialize novel therapies for sickle cell disease (SCD) and beta thalassemia. Request for Sample copy of this Report @ Key Market Takeaways: The North America sickle cell disease market is expected to exhibit a CAGR of 16.2%% during the forecast period, owing to increasing number of product launches. For instance, in November 2019, Novartis International AG, a pharmaceutical company, announced that they had received the U.S. Food Drug and Administration approval for Adakveo (crizanlizumab). The Adakveo (crizanlizumab) product is used for the treatment of pain induced in patients due to sickle cell diseases. Among drug type, voxelotor segment is estimated to be valued at US$ 342.2 million in 2021 and is projected to increase to US$ 1,243.1 million by 2028, witnessing a CAGR of 20.2% during the forecast period. Voxelotor is a hemoglobin S polymerization inhibitor, which is indicated for sickle cell disease in adults and pediatric patients of 12 years age and older. For instance, in 2019, Global Blood Therapeutics (GBT), announced to receive the U.S. Food Drug and Administration approval for Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD). Among country, the U.S. is estimated to hold dominant position in the market in 2021 and is estimated to account for a share of 94.7% in 2021 in the U.S. and is expected to exhibit a CAGR of 16.3% over the forecast period. The key players in the market are focusing on product launches and distribution agreements in the U.S., which is expected to boost the growth of the sickle cell disease market in the U.S. For instance, in August 2018, ADDMEDICA, a pharmaceutical company, announced the distribution agreement with Medunik U.S.A, a pharmaceutical company, for the distribution of Siklos (used for the treatment of SCD) in the U.S. Competitive Landscape: Key players operating in the North America sickle cell disease market include Novartis International AG, Bristol-Myers Squibb Company, Bluebird Bio, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., and Imara, Inc. Buy-Now this Research Report @ Market Segmentation: Related Market Intelligence Reports: Hemoglobinopathy Treatment Drugs Market, by Drug Type (Analgesics, Antibiotics, ACE Inhibitors, Hydroxyurea, and Others), by Disease Type (Thalassemia, Sickle Cell Disease, and Other Hb Variants Diseases), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027 Read more: Sickle Cell Anemia Therapeutics Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 Read more: About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. Follow Us: LinkedIn | Twitter

Pune, India, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The global sickle cell disease treatment market size is expected to reach USD 7.71 billion in 2027, exhibiting a CAGR of 18.5% during the forecast period. The unmet needs of patients and lack of novel therapies has resulted in research grants from governments, which, in turn, will promote the growth of the market, states Fortune Business Insights, in a report, titled “Sickle Cell Disease Treatment Market Size, Share & Covid-19 Impact Analysis, By Treatment Modality (Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy (Hydroxyurea and Branded Drugs (Endari, Adakveo, Oxbryta, Zynteglo, CTX001, Mitapivat, and FT-4202))), By End User (Hospitals, Specialty Clinics, and Others), and Regional Forecast, 2020-2027.” The market size stood at USD 1.35 billion in 2019. The entire world is fighting with the COVID-19 pandemic, which has severely disrupted trades across the globe. The authorities of several countries have initiated lockdown to prevent the spread of this deadly virus. Such plans have caused disturbances in the production and supply chain. But, with time and resolution, we will be able to combat this stern time and get back to normality. Our well-revised reports will help companies receive in-depth information about every market's present scenario so that you can adopt the necessary strategies accordingly. Request a Sample Copy of the Research Report: The sickle cell disease treatment market highpoints a comprehensive study of the market. It also offers essential facts about prominent players, besides revealing data about central regions in the market. The report includes key drivers and trends prevailing in the industry. Significant development, along with COVID’s impact, is covered in the study. FDA Product Approval to Intensify Business The introduction of innovative drugs and therapies to treat sickle cell diseases can spur lucrative opportunities for the market. For instance, in 2017, FDA approved Emmaus Life Sciences product Endari to treat patients with sickle cell disease aged five years and older. Moreover, the approval of three products by the regulatory bodies such as the FDA and EMA will foster the market's healthy growth. For instance, Oxbryta (Global Blood Therapeutics), Adakveo (Novartis AG), and Endari (Emmaus Life Sciences) are being utilized in the treatment of the disease. Oxbryta has been approved ahead of its statutory deadline. Moreover, products such as Zynteglo, CTX001, Mitapivat, and FT-4202 are expected to receive approval in the forthcoming years, which, in turn, will enable speedy expansion of the market. For instance, CTX001 has been granted EMA’s priority medicines (PRIME) designation in Europe. To get to know more about the short-term and long-term impacts of COVID-19 on this market, please visit: Postponement of Surgeries to Diminish Product Demand Amid Coronavirus Delay in non-urgent surgeries has resulted in a major drop in the number of BMT and blood transfusion procedures. The pandemic severely affected the demand and blood donor base. Moreover, lockdown and travel restrictions have led to a decline in the number of donors and the cancellation of numerous blood drives worldwide. For instance, U.S. blood centers witnessed a 30% decline in blood drives scheduled for the rest of the year, leading to about 250,000 missed donations. Furthermore, according to American Red Cross Blood Services, more than 50,000 blood drives have been canceled or moved due to the pandemic. These aforementioned factors reveal the enormous loss encountered by the sickle cell disease treatment industry during the coronavirus. Novartis AG to Dominate the Market Novartis AG accounted for the maximum share in the global market. The company entered the market with the approval of Adakveo in 2019. The drug can reduce the sickle cell pain crises by 45% in the clinical trials and hence is. Therefore, increasing demand for Adakveo among patients is expected to reinforce the company’s position. Quick Buy - Sickle Cell Disease Treatment Market Research Report: Strong Government Support to Support Growth in the U.S. The U.S market size stood at USD 0.71 billion in 2019 and is expected to remain dominant during the forecast period. The growth in the region is attributed to improving access to SCD treatment and potential pipeline candidates. The strong government support in the U.S. will further foster the healthy development of the market. According to the Center for International Blood and Marrow Transplant Research, in 2017, 157 hematopoietic cell transplants were performed in 2017 in the U.S for SCD. The number of BMT increased by 35.3% during 2013-2017. These factors together are expected to favor growth in the region. Key Development: September 2020: Global Blood Therapeutics, Inc. signed an exclusive agreement with Biopharma-MEA to distribute Oxbryta in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. The Report Lists the Key Players in the Sickle Cell Disease Treatment Market: Novartis AG (Basel, Switzerland) Global Blood Therapeutics Inc. (California, U.S.) Emmaus Medical Inc. (California, U.S.) Addmedica (Paris, France) Medunik USA Inc. (Pennsylvania, U.S.) Bristol-Myers Squibb Company (New York City, U.S.) Other prominent players Have Any Query? Ask Our Experts: Table of Contents: Introduction Research Scope Market Segmentation Research Methodology Definitions and Assumptions Executive Summary Market Dynamics Market Drivers Market Restraints Market Opportunities Key Insights Overview of Sickle Cell Disease Treatment Services Reimbursement Scenario – For Key Countries/ Regions Overview of Sickle Cell Disease Treatment Policies – For Key Countries Technological Advancements in Sickle Cell Disease Treatment State of Telehealth Adoption – For Key Countries/ Regions Major Sickle Cell Disease Treatment Service Providers – For Key Countries Internet Users & Penetrations Statistics Growth in Usage of Telehealth Technology Among Physicians Key Industry Developments - Mergers, Acquisitions and Partnerships Impact of COVID-19 on Sickle Cell Disease Treatment Market Global Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2016-2027 Key Findings / Summary Market Analysis, Insights and Forecast – By Treatment Modality Bone Marrow Transplant Blood Transfusion Pharmacotherapy Hydroxyurea Branded Drugs Endari Adakveo Oxbryta Zyntelgo CTX001 Mitapivat FT-4202 Market Analysis, Insights and Forecast – By End User Hospitals Specialty Clinics Others Market Analysis, Insights and Forecast – By Geography U.S. Europe Rest of World TOC Continued….! Get your Customized Research Report: SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION: Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc. Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility Number of procedures and average price of procedures Replacement rate and pricing of capital equipment Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities Market & technological trends, new product developments, product pipeline. Have a Look at Related Reports: Deep Brain Stimulation (DBS) Devices Market Share & Industry Analysis, By Product Type (Dual Channel Deep Brain stimulators, Single Channel Deep Brain Stimulators), By Application (Parkinson's Disease, Dystonia, Essential Tremor, Others), By End User (Hospitals, Specialty Clinics, Others) and Regional Forecast, 2019-2026 Biomarkers Market Share & Industry Analysis, By Indication (Oncology, Cardiology, Neurology, and Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026 Neuroendoscopy Devices Market Share & Industry Analysis, By Product Type (Rigid Neuroendoscopes, Flexible Neuroendoscopes), By Application Type (Transnasal Neuroendoscopy, Intraventricular Neuroendoscopy, Transcranial Neuroendoscopy), By End User (Hospitals, Specialty Clinics, Others) and Regional Forecast, 2019-2026 Ophthalmic Diagnostic Devices Market Share & Industry Analysis, By Product Type (Optical Coherence Tomography, Aberrometer & Topography Systems, Fundus Camera, Ophthalmic Ultrasound, and Other Ophthalmic Devices), By End-user (Hospitals, Ophthalmic Clinics, Others), and Regional Forecast, 2019-2026 Internet of Medical Things (IoMT) Market Share & Industry Analysis, By Product Type (Stationary Medical Devices, Implanted Medical Devices, Wearable External Medical Devices), By Application (Telemedicine, Medication Management, Patient Monitoring, Others), By End User (Healthcare Providers, Patients, Government Authorities, Others) and Regional Forecast, 2019-2026 About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us: Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India. Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: sales@fortunebusinessinsights.com Fortune Business Insights™ LinkedIn | Twitter | Blogs